August 15, 2019

Prostaglandin Choice Can Improve Synchronization Success

DULUTH, Georgia. (August 15, 2019) — “For dairy producers, controlling reproduction is one of the fastest ways to make an economic impact,” stated Stephen Foulke, DVM, DABVP, Boehringer Ingelheim. “And the key to successful breeding is making sure we achieve complete luteal regression as quickly as possible.” 

Preparing Cattle for Breeding

The corpus luteum (CL) is a transient structure on the ovary that produces the hormone progesterone to maintain pregnancy. In an OvSynch program, prostaglandins (PGF) are used to accelerate the regression of the CL. After injection of PGF, blood levels of progesterone typically drop in about 30 hours. Once the CL regresses, the follicle produces estrogen, which brings about standing heat. 

A Difference in Prostaglandins

“We used to think that the prostaglandins worked like turning off a light switch,” Dr. Foulke said. “But in reality, it appears that the uterus sends pulses to the corpus luteum, so it’s more like knocking at the door; it requires signaling over time to bring about luteal regression.”

Currently, there are two PGFproducts approved for luteolysis in lactating dairy cattle: cloprostenol sodium, which has a half-life of approximately 3 hours, and dinoprost tromethamine, with a half-life of about 8 minutes.1

“While dinoprost is quickly metabolized in the lungs and blown off, cloprostenol is metabolized in the kidneys, so it remains in the body longer,” explained Dr. Foulke. That means the latter may have more opportunities for signaling the CL.

A Faster Drop in Progesterone

In a study of lactating dairy cows, those treated with cloprostenol demonstrated a more rapid drop in serum progesterone in the first 12 hours after injection than those treated with dinoprost.2 This precipitous drop in progesterone appeared to increase the amount of estrogen produced by the follicle, potentially due to more pulses of luteinizing hormone, which encourages dominant follicle growth. 

Putting Prostaglandins to the Test

A field study in a large dairy herd compared the use of cloprostenol and dinoprost in lactating cows.3 In the 78 percent of cows inseminated on days 3 and 4 after treatment, cloprostenol increased estrus detection rates in first-parity cows by 42.4 percent, compared to 34.0 percent in cows treated with dinoprost. First-parity cows treated with cloprostenol also experienced higher pregnancy rates of 38.3 percent versus 34.4 percent in dinoprost-treated cows. 

Researchers surmised that the faster drop in progesterone and the ensuing rise in estrogen may be responsible for the increased rates of estrus detection and conception. 

Choosing the Right OvSynch Protocol

“The best synchronization protocol is the one you can get done on your farm consistently and accurately,” advised Dr. Foulke. He recommends working with your veterinarian to determine the fertility program that best fits your management style.

“As we increase our ability to control fertility, we can actually change the voluntary waiting period,” concluded Dr. Foulke. “While it has traditionally been 60 days, we can now push it out to 70 or 80 days, because we know we can get those cows bred.”

References: 

1 Martins JP, Neuder LM, Policelli RK, et al. Effects of cloprostenol sodium at final prostaglandin F of OvSynch on complete luteolysis and pregnancy per artificial insemination in lactating dairy cows. J Dairy Sci 2011;94(6):2815–2824.

2 Martins JP, Policelli RK, Pursley JR. Luteolytic effects of cloprostenol sodium in lactating dairy cows treated with G6G/Ovsynch. J Dairy Sci 2011;94(6):2806-–2814.

3 Pursley JR, Martins JP, Wright C, Stewart ND. Compared to dinoprost tromethamine, cloprostenol sodium increased rates of estrus detection, conception and pregnancy in lactating dairy cows on a large commercial dairy. Theriogenol 2012;78(4):823–829.

***

Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention. 

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas of human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales. 

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources, with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment. 

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.

 

About Boehringer Ingelheim Animal Health

Boehringer Ingelheim is the second largest animal health business in the world. We are committed to creating animal well-being through our large portfolio of advanced, preventive healthcare products and services. With net sales in 2017 of 3.9 billion euros ($4.4 billion) and around 10,000 employees worldwide, we are present in more than 150 markets. For more information, visit here: https://www.boehringer-ingelheim.com/animal-health/overview.    

 

©2019 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All Rights Reserved. BOV-2193-PHA0419